Does BENDAMUSTINE Cause Second primary malignancy? 140 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 140 reports of Second primary malignancy have been filed in association with BENDAMUSTINE (VIVIMUSTA). This represents 0.7% of all adverse event reports for BENDAMUSTINE.
140
Reports of Second primary malignancy with BENDAMUSTINE
0.7%
of all BENDAMUSTINE reports
44
Deaths
59
Hospitalizations
How Dangerous Is Second primary malignancy From BENDAMUSTINE?
Of the 140 reports, 44 (31.4%) resulted in death, 59 (42.1%) required hospitalization, and 8 (5.7%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for BENDAMUSTINE. However, 140 reports have been filed with the FAERS database.
What Other Side Effects Does BENDAMUSTINE Cause?
Off label use (2,578)
Disease progression (2,456)
Pyrexia (1,322)
Neutropenia (1,256)
Drug ineffective (1,135)
Febrile neutropenia (1,005)
Pneumonia (975)
Thrombocytopenia (967)
Covid-19 (892)
Anaemia (817)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which BENDAMUSTINE Alternatives Have Lower Second primary malignancy Risk?
BENDAMUSTINE vs BENDROFLUMETHIAZIDE
BENDAMUSTINE vs BENIDIPINE
BENDAMUSTINE vs BENLYSTA
BENDAMUSTINE vs BENRALIZUMAB
BENDAMUSTINE vs BENSERAZIDE